Analyzing Eurofins: Growth Stock with a Defensive Edge

What makes Eurofins a rare blend of safety and growth?

In today’s volatile market environment, Eurofins Scientific stands out with a compelling proposition: the ability to deliver both resilience and sustained growth. As a global leader in testing and laboratory services, Eurofins operates in different sectors (food, pharmaceuticals, environmental, and clinical diagnostics) where demand is not only recurring but steadily rising. This growth is due to many factors including increasingly stringent regulations or heightened health awareness.

But Eurofins is more than just a defensive play. Behind its essential services lies a robust growth engine. With a network of over 900 laboratories in more than 50 countries, the company has scaled efficiently through a blend of organic expansion and strategic acquisitions, building a decentralized but synergistic global platform.

This article examines what sets Eurofins apart. I will also outline the key risks and opportunities, provide my fair value estimate and highlight potential buy zones for investors who may find the stock appealing.

Company overview

Eurofins is structured into 4 strategic business units (Life, Biopharma, Diagnostic Services & Products, and Consumer & Technology Products Testing) each delivering testing and analysis services across industries.

1. Life (41% of revenue)

The life business unit is dedicated to safety, quality and sustainability in food, agricultural, and environmental domains. It conducts analytical testing on food and feed products to detect contaminants, allergens, and verify nutritional content. In agriculture, Eurofins supports crop and soil analysis, promoting sustainable farming practices and protecting food supply chains. Environmental testing services span air, water, and soil analysis, enabling clients to monitor pollution levels and comply with environmental regulations.

2. Biopharma (29% of revenue)

The biopharma unit serves pharmaceutical and biotechnology companies by offering comprehensive laboratory services that support the entire drug development lifecycle. From discovery and preclinical research to clinical trials and manufacturing quality control, Eurofins provides expertise in chemistry, microbiology, formulation, and stability testing. The unit also covers agroscience testing and offers specialized genomics and forensic services. With its deep scientific knowledge and regulatory expertise, this division plays a crucial role in helping clients bring safe, effective therapeutics to market efficiently.

3. Diagnostic services & product (20% of revenue)

Diagnostic services & products is Eurofins’ contribution to clinical and medical testing. This business unit develops and delivers advanced diagnostic solutions, including molecular diagnostics, and laboratory-developed tests in areas such as hormonal imbalances, autoimmune disorders, and infectious diseases. It also manufactures in-vitro diagnostic products, including instruments and assay reagents used in clinical labs and point-of-care settings. By integrating diagnostics with laboratory innovation, this segment enhances healthcare decision-making and supports better patient outcomes.

4. Consumer & technology products testing (10% of revenue)

The consumer & technology products testing unit focuses on evaluating the safety, quality, and regulatory compliance of everyday products. It tests a wide array of items (from toys and cosmetics to textiles and electronics) ensuring they meet local and international safety standards. This unit also conducts advanced material sciences testing, examining packaging properties, chemical composition, and mechanical durability.

A serial acquirer

From its IPO in 1997, Eurofins pursued an aggressive acquisition approach starting with environmental and food safety, and later moving into pharmaceutical, genomics, diagnostics, and materials science labs.

In 2024 alone, Eurofins completed 31 acquisitions (12 in North America, 15 in Europe, and 4 across the rest of the world) aimed at strengthening its technological capabilities, expanding its service offerings, and enhancing its global footprint. In Q1 2025 Eurofins closed 11 acquisitions, adding over 160M€ in revenues.

For years, Eurofins’ rapid-fire acquisition strategy was central to its expansion, transforming it from a niche lab in France into a global testing powerhouse. This aggressive M&A spree (often involving dozens of deals annually) allowed Eurofins to quickly scale into new geographies and service lines. However, the speed and scale of these acquisitions also sparked investor concerns over the company’s rising debt burden and the sustainability of its financial structure.

By the late 2010s, Eurofins was taking on substantial leverage to fund its deal-making. The company often prioritized growth and market share over near-term profitability, leading to a spike in net debt and pressure on its balance sheet. Credit rating agencies and analysts began to flag risks around integration challenges and capital intensity.

In recent years, however, Eurofins has made deliberate moves to address these concerns. Management began shifting from a high-velocity M&A model toward a more disciplined approach, focusing on strategic bolt-on acquisitions and optimizing existing operations. As a result, the company has materially improved its leverage metrics. The current debt leverage is around 2x EBITDA (it was 3.6x in 2019, 3x being the risk threshold).

Shadows behind the business

Eurofins Scientific has increasingly come under fire for what many critics view as a pattern of questionable corporate practices, marked by financial opacity, governance entanglements, and ethical lapses. Central to the unease is the company’s apparent tendency to massage certain financial metrics, selectively emphasizing adjusted figures that paint a rosier picture of its performance than standard accounting might allow. This raises legitimate concerns that Eurofins may be presenting an overly flattering narrative to the market.

Such skepticism reached a boiling point in June 2024, when prominent short-seller Muddy Waters published a scathing report accusing Eurofins of inflating earnings and overstating cash balances. The 35-page document pointed to a web of related-party transactions involving CEO Gilles Martin, whose private holding company allegedly sold properties to Eurofins and then leased them back at above-market rents. These arrangements, the report claimed, allowed insiders to quietly extract value from the business under the guise of routine operations. The conclusion was blunt: Eurofins, according to Muddy Waters, appeared “optimized for malfeasance”.

These allegations are especially troubling in light of the company’s complex and opaque ownership structure. Although Martin owns a relatively modest economic stake, he wields significant voting power through his vehicle Analytical Bioventures, giving him effective control over Eurofins’ strategic direction. This dual-class setup limits accountability and amplifies concerns about conflicts of interest, particularly when insider transactions are involved.

The company’s operational history offers further reasons for concern. Eurofins has previously been implicated in multiple cases of data manipulation and regulatory noncompliance. In the US, employees were caught falsifying lab results and billing for services that did not meet proper standards, leading to federal investigations, legal settlements, and reputational damage. These incidents suggest a recurring failure in internal oversight and hint at a corporate culture where procedural rigor can be compromised in pursuit of growth or profit.

In sum, while Eurofins has positioned itself as a global leader in testing and laboratory services, its governance model, financial practices, and compliance record have drawn a cloud of suspicion. While such characteristics are not uncommon in family-controlled enterprises, they nonetheless represent an added layer of risk that investors must carefully weigh.

A fragmented growing market

This chart illustrates one of the key drivers behind the company’s success: its Environmental division, a subsegment of the Life Sciences business unit. The data highlights how this sector has been expanding at a pace that consistently outstrips GDP growth, underscoring its strategic importance.

The pharmaceutical analytical testing market is projected to grow at over 9% annually through 2030. The growth of these underlying markets is fueled by tightening regulatory standards and increasing health awareness in both developed and emerging economies. As the need for rigorous testing continues to escalate, the sector remains well-positioned for sustained expansion.

Moreover, despite rapid consolidation in recent years, the market remains highly fragmented, offering ample opportunities for further acquisitions.

---

In the following sections, you will find detailed insights into key metrics, fair price estimation, a comprehensive SWOT analysis (strengths, weaknesses, opportunities, and risks), and precise buy zone identification. Subscribe now to unlock full access to this newsletter, including exclusive analyses, portfolio tracking, screeners and curated stock picks

---